Key result
Botulinum toxin-A is linked to a ~12-N reduction in wrist spasticity at 6 weeks.
Why the study?
Botulinum toxin-A reduces resistance to passive movement on clinical scales, but discriminating and quantifying the underlying neural, elastic, and viscous components of wrist hyper-resistance was needed to better understand its effects.
Does intramuscular botulinum toxin-A injection reduce the neural, elastic, and viscous components of passive wrist extension hyper-resistance in adults with chronic stroke or cerebral palsy?
Cohort (n=18)
Non-blinded observational study (assessors unaware of BoNT treatment dose)
No
Does intramuscular botulinum toxin-A injection reduce the neural, elastic, and viscous components of passive wrist extension hyper-resistance in adults with chronic stroke or cerebral palsy?
Answers are grounded in this paper and cite their sources.
Instrumented quantification using the NeuroFlexor demonstrates that botulinum toxin-A selectively and dose-dependently reduces the neural component of wrist hyper-resistance without affecting non-neural elastic or viscous tissue properties.
BACKGROUND: Botulinum toxin-A (BoNT) is widely used to manage focal upper limb spasticity and is effective in reducing resistance to passive movement, as measured with the modified Ashworth scale. Discrimination and quantification of the underlying neural and non-neural components of hyper-resistance may further improve understanding of the effect of BoNT. OBJECTIVE: To explore the effects of BoNT on neural (NC), non-neural elastic (EC), and viscous (VC) components of resistance to passive wrist extension in adults with stroke or cerebral palsy and the association between the effects on wrist hyper-resistance components and clinical spasticity, pain and motor function scales. DESIGN: Pre-experimental study with pre- and post-intervention measurements at 6 and 12 weeks. SETTING: An outpatient clinic of a hospital. PARTICIPANTS: Adults with chronic stroke or cerebral palsy indicated for BoNT treatment for hyper-resistance in the wrist (N = 18). INTERVENTIONS: BoNT injections in the wrist and/or finger flexor muscles. MAIN OUTCOME MEASURES: Wrist hyper-resistance components, using the NeuroFlexor, and clinical scales (modified Ashworth scale, Tardieu scale, passive wrist extension, pain, Fugl-Meyer motor assessment of the upper extremity, and action research arm test). No significant correlations were found between change scores in wrist hyper-resistance components and clinical scales. CONCLUSIONS: BoNT affected the neural component of resistance to passive wrist extension, while leaving the non-neural elastic and viscous components unaffected. This instrumented approach to quantify the effects of BoNT in the wrist and finger flexor muscles on the components of wrist hyper-resistance may have an added value for BoNT treatment evaluation in clinical practice.
No takes yet. Share an insight, caveat, or question.
Andringa et al. (2021) conducted a cohort in Wrist hyper-resistance due to chronic stroke or cerebral palsy (n=18). Botulinum toxin-A (onabotulinumtoxinA or incobotulinumtoxinA) intramuscular injection was evaluated on Neural component (NC) of resistance to passive wrist extension measured by the NeuroFlexor at 6 and 12 weeks (p=<0.001). Botulinum toxin-A reduced the median neural component of passive wrist extension resistance from 20.47 N at baseline to 8.51 N at 6 weeks and 11.13 N at 12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: